Skip to main content
. 2022 Apr 5;198(1):62–72. doi: 10.1111/bjh.18162

FIGURE 2.

FIGURE 2

Progression‐free survival in Chinese patients with relapsed/refractory (R/R) B‐cell malignancies receiving zanubrutinib by dose regimen. There was no significant difference between the two dose groups as indicated by the log‐rank test (p = 0.25)